← HERON THERAPEUTICS, INC. /DE/
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.3m |
$30.8m
+2305.55%
|
$77.5m
+151.81%
|
$146.0m
+88.41%
|
$88.6m
-39.28%
|
$86.3m
-2.59%
|
$107.7m
+24.70%
|
$127.0m
+17.99%
|
$144.3m
+13.57%
|
$154.9m
+7.36%
|
$150.7m
-2.71%
|
|
| Cost of Revenue | $35k |
$4.6m
+13008.57%
|
$27.5m
+499.65%
|
$61.6m
+123.97%
|
$36.2m
-41.27%
|
$46.0m
+27.17%
|
$54.9m
+19.24%
|
$65.1m
+18.64%
|
$38.6m
-40.64%
|
$41.3m
+6.98%
|
$43.5m
+5.27%
|
|
| Gross Profit | $1.2m |
$26.2m
+2004.42%
|
$50.0m
+90.85%
|
$84.3m
+68.83%
|
$52.4m
-37.82%
|
$40.3m
-23.12%
|
$52.8m
+30.93%
|
$61.9m
+17.31%
|
$105.6m
+70.55%
|
$113.6m
+7.50%
|
$107.2m
-5.61%
|
|
| Research and Development Expense | $103.1m | $138.6m | $140.0m | $167.4m | $174.5m | $130.8m | $107.5m | $55.9m | $16.7m | $12.4m | $12.5m | |
| Selling and Marketing Expense | $47.7m | $56.6m | $64.6m | $89.8m | $63.9m | $87.2m | $82.5m | $67.6m | $47.1m | $49.1m | $105.1m | |
| General and Administrative Expense | $21.4m | $25.6m | $29.3m | $37.9m | $42.2m | $40.2m | $37.4m | $49.0m | $53.4m | $54.6m | $54.0m | |
| Operating Lease, Expense | — | — | — | $3.1m | $3.9m | $3.7m | $2.8m | $2.9m | $3.0m | $3.1m | — | |
| Operating Expenses | $172.2m | $225.3m | $261.4m | — | — | — | — | — | — | — | $161.2m | |
| Operating Income (Loss) | ($170.9m) |
($194.6m)
-13.83%
|
($183.9m)
+5.46%
|
($210.7m)
-14.55%
|
($228.2m)
-8.29%
|
($217.8m)
+4.53%
|
($174.7m)
+19.82%
|
($110.6m)
+36.67%
|
($11.5m)
+89.58%
|
($2.5m)
+77.98%
|
($10.5m)
-312.02%
|
|
| Other Nonoperating Income (Expense) | $436k | ($38k) | $1.8m | $158k | ($847k) | ($878k) | ($6.5m) | $560k | $430k | $1.3m | — | |
| Interest Expense (non-operating) | $2.7m | $3.9m | $2.7m | $1.5m | $1.9m | $2.4m | $2.5m | $3.9m | $6.0m | $9.6m | $9.6m | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Net Income (Loss) Attributable to Parent | ($173.1m) |
($197.5m)
-14.06%
|
($178.8m)
+9.44%
|
($204.7m)
-14.49%
|
($227.3m)
-11.00%
|
($220.7m)
+2.90%
|
($182.0m)
+17.52%
|
($110.6m)
+39.26%
|
($13.6m)
+87.72%
|
($20.2m)
-48.71%
|
($30.9m)
-53.21%
|
|
| Earnings Per Share, Basic | — | — | — | — | — | ($2.24) | ($1.67) | ($0.80) | ($0.09) | ($0.12) | ($0.18) | |
| Earnings Per Share, Diluted | — | — | — | — | — | ($2.24) | ($1.67) | ($0.80) | ($0.09) | ($0.12) | ($0.18) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | — | 109k | 138.1m | 152.4m | 166.7m | 164.9m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | — | 109k | 138.1m | 152.4m | 166.7m | 164.9m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | — | — | — | $356.7m | $316.8m | $304.2m | $282.3m | $172.6m | $117.2m | $116.1m | — |